Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Non-Current Liabilities (2018 - 2022)

Ovid Therapeutics filings provide 5 years of Total Non-Current Liabilities readings, the most recent being $26.1 million for Q1 2022.

  • Quarterly Total Non-Current Liabilities rose 59.67% to $26.1 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $26.1 million through Mar 2022, up 59.67% year-over-year, with the annual reading at $14.8 million for FY2021, 54.18% down from the prior year.
  • Total Non-Current Liabilities hit $26.1 million in Q1 2022 for Ovid Therapeutics, up from $14.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $32.3 million in Q4 2020 and bottomed at $8.8 million in Q4 2018.
  • Average Total Non-Current Liabilities over 5 years is $15.2 million, with a median of $11.1 million recorded in 2019.
  • The largest annual shift saw Total Non-Current Liabilities soared 198.46% in 2020 before it tumbled 64.0% in 2021.
  • Ovid Therapeutics' Total Non-Current Liabilities stood at $8.8 million in 2018, then grew by 22.34% to $10.8 million in 2019, then skyrocketed by 198.46% to $32.3 million in 2020, then crashed by 54.18% to $14.8 million in 2021, then surged by 76.37% to $26.1 million in 2022.
  • Per Business Quant, the three most recent readings for OVID's Total Non-Current Liabilities are $26.1 million (Q1 2022), $14.8 million (Q4 2021), and $10.1 million (Q3 2021).